Speech for ITIer on 2/10/2015 to introduce scope of BIO industry, especially for pharmaceutical industry.
In the next session, a brief introduction to Drug Development and Drug Marketing.
Finally, the career opportunities which maybe suitable for a international business talents are concluded.
Speech for ITIer on 2/10/2015 to introduce scope of BIO industry, especially for pharmaceutical industry.
In the next session, a brief introduction to Drug Development and Drug Marketing.
Finally, the career opportunities which maybe suitable for a international business talents are concluded.
OBI Pharma presentation at JP Morgan Healthcare Conference 2018 - Chinese Version
1. The 36th J.P. Morgan
Annual Healthcare
Conference
2018年1月 9~11日, 美國舊金山
2. Safe Harbor Statement
This presentation contains certain forward-looking
statements.
These forward-looking statements may be identified by
words such as ‘believes’, ‘expects’, ‘anticipates’,
‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’
or similar expressions or by discussion of, among other
things, strategy, goals, plans or intentions. Various
factors may cause actual results to differ materially in
the future from those reflected in forward-looking
statements contained in this presentation, among
others:
1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and
economic conditions;
3 delay or inability in obtaining regulatory approvals
or bringing products to market;
4 fluctuations in currency exchange rates and general
financial market conditions;
5 uncertainties in the discovery, development or
marketing of new products or new uses of existing
products, including without limitation negative
results of clinical trials or research projects,
unexpected side-effects of pipeline or marketed
products;
6 increased government pricing pressures;
7 interruptions in production
8 loss of or inability to obtain adequate protection for
intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.
OBI Pharma cautions that this foregoing list of factors is
not exhaustive. There may also be other risks that
management is unable to predict at this time that may
cause actual results to differ materially from those in
forward-looking statements. You are cautioned not to
place undue reliance on these forward-looking
statements, which speak only as of the date on which
they are made. OBI undertakes no obligation to update
publicly or revise any forward-looking statements.
Any statements regarding earnings growth is not a
profit forecast and should not be interpreted to mean
that OBI’s earnings or earnings per share for this year
or any subsequent period will necessarily match or
exceed published earnings or earnings per share
forecasts of OBI Pharma, Inc.
2
3. 3
… with an innovative and balanced portfolio
Re-inventing
OBI as a Global Oncology Company…
23. OBI-3424比 Sorafenib具更強的抗癌作用
0 4 7 11 14 18 21 25 28 32 35
Days
TumorArea(mm2)
2
4
6
8
10
12
14
Saline
Sorafenib
OBI-3424 1.25
OBI-3424 2.5
23
可觀察到
顯著差異
NOTE: Doses in mg/kg
SOURCE: Duan et al., Broad In Vitro and In Vivo Antitumor Activity of TH-3424: Preclinical Rationale for a
Highly Selective AKR1C3 Prodrug for Treating Cancer AACR Annual Meeting 2016, Abstract #1369
24. PDX Model (T-ALL 31)
Control
Group
OBI-3424
Treated
Group
OBI-3424組的白血病骨髓浸潤明顯降低
實驗組小鼠與控制
組小鼠在無事件存
活期(Event-Free
Survival, EFS)有
明顯差異
耐受良好
Days post-treatment initiation
%huCD45+inthePB
為一以AKR1C3酵素為生物標記,治療侵襲性以及對化療有抗藥性之T細胞急性淋巴性白血病之新穎療法
25. Results of a Patient-Derived Xenograft (PDX)
Study of OBI-3424 in T-cell Acute Lymphoblastic
Leukemia (T-ALL) Presented at the AACR
“OBI-3424 is one of the most
effective drugs we have ever tested
against T-ALL in over 12 years of
evaluating drugs at the Children's
Cancer Institute in Australia using
preclinical models of aggressive
childhood ALL. We are incredibly
excited about the potential for OBI-
3424 to improve the treatment and
quality of life for patients with this
aggressive type of cancer and look
forward to having this potential
evaluated in clinical trials.” Professor Richard B. Lock
Head of the Leukemia Biology Program
Children's Cancer Institute in Australia
30. Adagloxad Simolenin臨床數據分別發
表於極具聲望之癌症會議
30
Dr Rugo 報告臨床數據結果 由 Dr Johnston 主持第一次
Adagloxad Simolenin 研討會
3–7 JUNE 2016 7–11 OCTOBER 2016
諮詢委員會會議 乳癌研討會一對一會議
Clinical Professor Hope S. Rugo of the Helen
Diller Family Comprehensive Cancer Center
at UCSF
Professor Stephen Johnston of The
Royal Marsden NHS Foundation
Trust
35. 浩鼎顧問委員會的新成員
35
Russell Greig, PhD
Global Biotech
Big Pharma R&D
VC/PE Perspective
Chi-huey Wong, PhD
Global Pioneer in
Glycan Science
Taiwan Biotech
Thought leader
Tillman Pierce, MD
Global Clinical Trials
Protocol Design
Biotech R&D
36. Michael Chang, PhD
創始人 & 主席
Amy Huang
總經理
經驗豐富的全球管理團隊
Tony Yu
研發長
Kevin Poulos
商務長
Max Chan
營運長
Mitch Che
營運長
OBI USA
Cristina
Chang
全球臨床開發
和醫療事務
副總
David
Hallinan
全球醫藥法規
副總
Sophia
Lee
統計副總
37